Which has better valuation & earnings, ATRC or PODD?

Insulet has higher revenue and earnings than AtriCure. Insulet is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 4.62 -$11.45M $0.21 231.14 Insulet $2.71B 3.72 $247.10M $5.35 27.13

Is ATRC or PODD more profitable?

Insulet has a net margin of 12.29% compared to AtriCure's net margin of 1.85%. Insulet's return on equity of 29.29% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Insulet 12.29% 29.29% 13.31%

Does the media prefer ATRC or PODD?

In the previous week, Insulet had 37 more articles in the media than AtriCure. MarketBeat recorded 56 mentions for Insulet and 19 mentions for AtriCure. AtriCure's average media sentiment score of 0.90 beat Insulet's score of 0.67 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 23 Very Positive mention(s) 2 Positive mention(s) 30 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ATRC or TFX?

AtriCure has higher earnings, but lower revenue than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 4.62 -$11.45M $0.21 231.14 Teleflex $1.99B 2.97 -$905.64M -$23.29 N/A

Is ATRC or TFX more profitable?

AtriCure has a net margin of 1.85% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Teleflex -39.67% 11.93% 5.44%

Does the media prefer ATRC or TFX?

In the previous week, AtriCure had 7 more articles in the media than Teleflex. MarketBeat recorded 19 mentions for AtriCure and 12 mentions for Teleflex. Teleflex's average media sentiment score of 0.93 beat AtriCure's score of 0.90 indicating that Teleflex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Teleflex 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MMED or ATRC?

In the previous week, AtriCure had 9 more articles in the media than MiniMed Group. MarketBeat recorded 19 mentions for AtriCure and 10 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.00 beat AtriCure's score of 0.90 indicating that MiniMed Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ATRC or HAE?

Haemonetics has higher revenue and earnings than AtriCure. Haemonetics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 4.62 -$11.45M $0.21 231.14 Haemonetics $1.33B 3.54 $97.31M $2.04 50.90

Is ATRC or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to AtriCure's net margin of 1.85%. Haemonetics' return on equity of 27.55% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Haemonetics 7.12% 27.55% 9.65%

Does the media favor ATRC or HAE?

In the previous week, Haemonetics had 1 more articles in the media than AtriCure. MarketBeat recorded 20 mentions for Haemonetics and 19 mentions for AtriCure. AtriCure's average media sentiment score of 0.90 beat Haemonetics' score of 0.67 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, LIVN or ATRC?

AtriCure has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.47B 3.01 -$242.47M $3.38 23.76 AtriCure $534.53M 4.62 -$11.45M $0.21 231.14

Is LIVN or ATRC more profitable?

LivaNova has a net margin of 12.82% compared to AtriCure's net margin of 1.85%. LivaNova's return on equity of 16.35% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% AtriCure 1.85% 2.34% 1.77%

Does the media refer more to LIVN or ATRC?

In the previous week, AtriCure had 16 more articles in the media than LivaNova. MarketBeat recorded 19 mentions for AtriCure and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.08 beat AtriCure's score of 0.90 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

AtriCure (ATRC) Competitors

$48.54 -0.73 (-1.48%)

As of 08/28/2026 04:00 PM Eastern

Compare

ATRC vs. PODD, TFX, MMED, HAE, and LIVN

Should you buy AtriCure stock or one of its competitors? AtriCure's main competitors and comparable companies include Insulet (PODD), Teleflex (TFX), MiniMed Group (MMED), Haemonetics (HAE), and LivaNova (LIVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does AtriCure compare to Insulet?

AtriCure (NASDAQ:ATRC) and Insulet (NASDAQ:PODD) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Insulet had 37 more articles in the media than AtriCure. MarketBeat recorded 56 mentions for Insulet and 19 mentions for AtriCure. AtriCure's average media sentiment score of 0.90 beat Insulet's score of 0.67 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	23 Very Positive mention(s)	2 Positive mention(s)	30 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of AtriCure shares are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Insulet has higher revenue and earnings than AtriCure. Insulet is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	4.62	-$11.45M	$0.21	231.14
Insulet	$2.71B	3.72	$247.10M	$5.35	27.13

AtriCure has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Insulet has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

AtriCure presently has a consensus target price of $49.89, indicating a potential upside of 2.78%. Insulet has a consensus target price of $195.40, indicating a potential upside of 34.64%. Given Insulet's higher possible upside, analysts plainly believe Insulet is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44

Insulet has a net margin of 12.29% compared to AtriCure's net margin of 1.85%. Insulet's return on equity of 29.29% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Insulet	12.29%	29.29%	13.31%

Summary

Insulet beats AtriCure on 9 of the 17 factors compared between the two stocks.

How does AtriCure compare to Teleflex?

AtriCure (NASDAQ:ATRC) and Teleflex (NYSE:TFX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

99.1% of AtriCure shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Comparatively, 0.7% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AtriCure has higher earnings, but lower revenue than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	4.62	-$11.45M	$0.21	231.14
Teleflex	$1.99B	2.97	-$905.64M	-$23.29	N/A

AtriCure currently has a consensus price target of $49.89, suggesting a potential upside of 2.78%. Teleflex has a consensus price target of $152.90, suggesting a potential upside of 9.36%. Given Teleflex's higher probable upside, analysts clearly believe Teleflex is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

AtriCure has a net margin of 1.85% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Teleflex	-39.67%	11.93%	5.44%

AtriCure has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Teleflex has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

In the previous week, AtriCure had 7 more articles in the media than Teleflex. MarketBeat recorded 19 mentions for AtriCure and 12 mentions for Teleflex. Teleflex's average media sentiment score of 0.93 beat AtriCure's score of 0.90 indicating that Teleflex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Teleflex	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AtriCure beats Teleflex on 11 of the 16 factors compared between the two stocks.

How does AtriCure compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and AtriCure (NASDAQ:ATRC) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

AtriCure has lower revenue, but higher earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.82	-$333M	-$0.68	N/A
AtriCure	$534.53M	4.62	-$11.45M	$0.21	231.14

MiniMed Group currently has a consensus price target of $21.62, indicating a potential upside of 7.54%. AtriCure has a consensus price target of $49.89, indicating a potential upside of 2.78%. Given MiniMed Group's higher possible upside, equities research analysts clearly believe MiniMed Group is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, AtriCure had 9 more articles in the media than MiniMed Group. MarketBeat recorded 19 mentions for AtriCure and 10 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.00 beat AtriCure's score of 0.90 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure has a net margin of 1.85% compared to MiniMed Group's net margin of 0.00%. AtriCure's return on equity of 2.34% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
AtriCure	1.85%	2.34%	1.77%

99.1% of AtriCure shares are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

AtriCure beats MiniMed Group on 11 of the 15 factors compared between the two stocks.

How does AtriCure compare to Haemonetics?

AtriCure (NASDAQ:ATRC) and Haemonetics (NYSE:HAE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Haemonetics has higher revenue and earnings than AtriCure. Haemonetics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	4.62	-$11.45M	$0.21	231.14
Haemonetics	$1.33B	3.54	$97.31M	$2.04	50.90

99.1% of AtriCure shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 4.0% of AtriCure shares are held by insiders. Comparatively, 2.1% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Haemonetics had 1 more articles in the media than AtriCure. MarketBeat recorded 20 mentions for Haemonetics and 19 mentions for AtriCure. AtriCure's average media sentiment score of 0.90 beat Haemonetics' score of 0.67 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

Haemonetics has a net margin of 7.12% compared to AtriCure's net margin of 1.85%. Haemonetics' return on equity of 27.55% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Haemonetics	7.12%	27.55%	9.65%

AtriCure presently has a consensus price target of $49.89, suggesting a potential upside of 2.78%. Haemonetics has a consensus price target of $97.56, suggesting a potential downside of 6.04%. Given AtriCure's stronger consensus rating and higher probable upside, research analysts plainly believe AtriCure is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

AtriCure and Haemonetics tied by winning 8 of the 16 factors compared between the two stocks.

How does AtriCure compare to LivaNova?

LivaNova (NASDAQ:LIVN) and AtriCure (NASDAQ:ATRC) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

97.6% of LivaNova shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LivaNova presently has a consensus target price of $83.50, indicating a potential upside of 3.96%. AtriCure has a consensus target price of $49.89, indicating a potential upside of 2.78%. Given LivaNova's higher probable upside, analysts clearly believe LivaNova is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, AtriCure had 16 more articles in the media than LivaNova. MarketBeat recorded 19 mentions for AtriCure and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.08 beat AtriCure's score of 0.90 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

LivaNova has a net margin of 12.82% compared to AtriCure's net margin of 1.85%. LivaNova's return on equity of 16.35% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
AtriCure	1.85%	2.34%	1.77%

AtriCure has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.47B	3.01	-$242.47M	$3.38	23.76
AtriCure	$534.53M	4.62	-$11.45M	$0.21	231.14

Summary

AtriCure beats LivaNova on 10 of the 17 factors compared between the two stocks.

Get AtriCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRC vs. The Competition

Export

Metric	AtriCure	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.47B	$5.86B	$7.20B	$12.91B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	231.15	25.92	273.16	25.45
Price / Sales	4.62	67.91	634.73	93.93
Price / Cash	155.08	33.03	76.74	53.00
Price / Book	4.78	6.18	12.98	6.14
Net Income	-$11.45M	$149.01M	$3.48B	$348.86M
7 Day Performance	-0.90%	-0.24%	0.13%	-0.80%
1 Month Performance	20.90%	6.18%	7.08%	4.13%
1 Year Performance	31.22%	6.30%	24.67%	15.17%

AtriCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRC AtriCure	2.6315 of 5 stars	$48.54 -1.5%	$49.89 +2.8%	+31.2%	$2.47B	$534.53M	231.15	1,300	News Coverage Analyst Forecast Insider Trade
PODD Insulet	4.7121 of 5 stars	$143.17 -1.5%	$195.40 +36.5%	-57.3%	$9.94B	$2.71B	26.79	5,400	Trending News
TFX Teleflex	3.4971 of 5 stars	$138.57 +0.2%	$152.90 +10.3%	+10.5%	$5.87B	$1.99B	N/A	15,500	Analyst Forecast Short Interest Increase
MMED MiniMed Group	2.1326 of 5 stars	$19.18 -3.8%	$21.62 +12.7%	N/A	$5.39B	$3.10B	N/A	2,800	News Coverage Lockup Expiration
HAE Haemonetics	2.6678 of 5 stars	$108.45 +0.0%	$97.56 -10.0%	+90.1%	$4.93B	$1.35B	53.14	3,009	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRC) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AtriCure (ATRC) Competitors